In This Article:
Roche has introduced the Elecsys PRO-C3 test for evaluating the liver fibrosis severity in individuals with signs of metabolic dysfunction–associated steatotic liver disease (MASLD).
The Elecsys PRO-C3 test, developed in collaboration with Nordic Bioscience, provides clinicians with a simple method to identify liver fibrosis severity, which is essential for timely medical intervention.
Roche highlighted that until recently, lifestyle changes were the only management strategy for MASLD, as no specific medications were available.
The test operates on Roche's cobas analysers and requires one assay, delivering outcomes in 18 minutes. This marks an improvement over existing diagnostic methods, potentially minimising healthcare expenses.
When used alongside the ADAPT formula, the test is said to offer a comprehensive evaluation of fibrosis severity.
The ADAPT score, which integrates PRO-C3 levels, age, platelet count and diabetes status, assists in distinguishing between significant and advanced fibrosis and cirrhosis.
This differentiation is vital for selecting suitable treatment options and detecting candidates for emerging therapies.
Roche plans to introduce software later in the year to automate the ADAPT score calculation, further enhancing the diagnosis process for liver fibrosis.
Roche Diagnostics CEO Matt Sause said: "The Elecsys PRO-C3 test addresses an urgent need in the diagnosis, staging, and management of liver fibrosis.
"With MASLD affecting a growing number of people worldwide and new treatments emerging, it is critical to detect fibrosis accurately and early. Our innovative solution simplifies the diagnostic process and eases the burden on healthcare services, providing a clear and rapid assessment while reducing the requirement for invasive biopsies."
Last month, Roche received breakthrough device designation from the US Food and Drug Administration for its computational pathology companion diagnostic VENTANA TROP2 (EPR20043) RxDx device.
"Roche introduces diagnostic test for liver fibrosis severity assessment" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.